Matches in SemOpenAlex for { <https://semopenalex.org/work/W83920437> ?p ?o ?g. }
Showing items 1 to 66 of
66
with 100 items per page.
- W83920437 endingPage "19106" @default.
- W83920437 startingPage "19106" @default.
- W83920437 abstract "19106 Background: Pemetrexed has been approved for the treatment of relapsed NSCLC and is characterized by excellent tolerance when appropriate vitamin supplementation is provided. Based on the relatively lack of myelosuppression, the current exploratory study investigates the feasibility of dosing frequency of 2 weeks Methods: Patients with relapsed NSCLC otherwise eligible to receive commercially available pemetrexed were enrolled. Patients were required to have a WBC > 2500/ul and platelets > 100000/ul and a ECOG status 0–3. Standard B12 supplementation as well as folic acid 2.5 mg daily were provided. Pemetrexed was dosed at 500 mg/m2 every 2 weeks, until disease progression. Response was assessed after the third administration. Results: Sixteen patients have been treated with the following characteristics: median age: 66, male:13, female:3, adenoca: 14; ECOG PS: 0: 1 pt, 1:4 pts, 2: 8 pts, 3: 3 pts; 8 patients received pemetrexed as 2nd line treatment, whereas 7 as 3rd and 1 as 4th. The median number of administrations were 4. Grade 3–4 neutropenia was noted in one patient and grade 3–4 thrombocytopenia in another. Dose delay was required in 2 instances. No prophylactic WBC growth factor was used. One patient required blood transfusion, whereas erythropoietin supplementation was provided as needed. Other significant toxicity included asthenia grade 3 (4 patients). Stable disease was noted in 10 patents and progression in 6, with a median TTP of 9 weeks. Conclusions: This preliminary study suggests that administration of standard dose pemetrexed every 2 weeks is feasible and well tolerated even in our particularly adverse group of patients. Larger studies are needed to further assess the clinical usefulness of such an accelerated regimen. No significant financial relationships to disclose." @default.
- W83920437 created "2016-06-24" @default.
- W83920437 creator A5020672371 @default.
- W83920437 creator A5022956074 @default.
- W83920437 creator A5057437471 @default.
- W83920437 date "2008-05-20" @default.
- W83920437 modified "2023-10-18" @default.
- W83920437 title "Feasibility of treatment of relapsed NSCLC with accelerated pemetrexed given every 2 weeks" @default.
- W83920437 doi "https://doi.org/10.1200/jco.2008.26.15_suppl.19106" @default.
- W83920437 hasPublicationYear "2008" @default.
- W83920437 type Work @default.
- W83920437 sameAs 83920437 @default.
- W83920437 citedByCount "2" @default.
- W83920437 crossrefType "journal-article" @default.
- W83920437 hasAuthorship W83920437A5020672371 @default.
- W83920437 hasAuthorship W83920437A5022956074 @default.
- W83920437 hasAuthorship W83920437A5057437471 @default.
- W83920437 hasConcept C126322002 @default.
- W83920437 hasConcept C141071460 @default.
- W83920437 hasConcept C143998085 @default.
- W83920437 hasConcept C197934379 @default.
- W83920437 hasConcept C2776164570 @default.
- W83920437 hasConcept C2776694085 @default.
- W83920437 hasConcept C2777063308 @default.
- W83920437 hasConcept C2777240266 @default.
- W83920437 hasConcept C2777288759 @default.
- W83920437 hasConcept C2778239845 @default.
- W83920437 hasConcept C2778248108 @default.
- W83920437 hasConcept C2778375690 @default.
- W83920437 hasConcept C2778534260 @default.
- W83920437 hasConcept C71924100 @default.
- W83920437 hasConceptScore W83920437C126322002 @default.
- W83920437 hasConceptScore W83920437C141071460 @default.
- W83920437 hasConceptScore W83920437C143998085 @default.
- W83920437 hasConceptScore W83920437C197934379 @default.
- W83920437 hasConceptScore W83920437C2776164570 @default.
- W83920437 hasConceptScore W83920437C2776694085 @default.
- W83920437 hasConceptScore W83920437C2777063308 @default.
- W83920437 hasConceptScore W83920437C2777240266 @default.
- W83920437 hasConceptScore W83920437C2777288759 @default.
- W83920437 hasConceptScore W83920437C2778239845 @default.
- W83920437 hasConceptScore W83920437C2778248108 @default.
- W83920437 hasConceptScore W83920437C2778375690 @default.
- W83920437 hasConceptScore W83920437C2778534260 @default.
- W83920437 hasConceptScore W83920437C71924100 @default.
- W83920437 hasIssue "15_suppl" @default.
- W83920437 hasLocation W839204371 @default.
- W83920437 hasOpenAccess W83920437 @default.
- W83920437 hasPrimaryLocation W839204371 @default.
- W83920437 hasRelatedWork W2013653055 @default.
- W83920437 hasRelatedWork W2014074349 @default.
- W83920437 hasRelatedWork W2090652903 @default.
- W83920437 hasRelatedWork W2112217407 @default.
- W83920437 hasRelatedWork W2115592617 @default.
- W83920437 hasRelatedWork W2143338141 @default.
- W83920437 hasRelatedWork W2361768249 @default.
- W83920437 hasRelatedWork W2397946790 @default.
- W83920437 hasRelatedWork W2412329359 @default.
- W83920437 hasRelatedWork W2418834791 @default.
- W83920437 hasVolume "26" @default.
- W83920437 isParatext "false" @default.
- W83920437 isRetracted "false" @default.
- W83920437 magId "83920437" @default.
- W83920437 workType "article" @default.